Back to first-pass browser

First-pass extracted concept

2-ANPC

Candidate: toolkit item1 source documents7 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Aliases

2-amino-1-benzamido-5-(2-(naphthalene-2-yl)-2-oxoethylidene)-4-oxo-4,5-dihydro-1-H-pyrrole-3-carboxamide, 2-aminopyrrole derivative

Extracted Explainers

What the tool is doing

2-ANPC is a 2-aminopyrrole derivative reported to downregulate HIF-1α expression in multiple cancer cell lines and in a 4T1 mouse tumor model. The abstract also describes it as a previously shown microtubule-targeting agent.

Source 1DOIPubMed

Resources required

The reported study used western blotting in breast, lung, and prostate cancer cell lines and a syngeneic 4T1 breast cancer mouse model. Mechanistic testing also used the proteasome inhibitor MG-132.

Source 1DOIPubMed

What problem it solves

The compound is presented as a scaffold for targeting HIF-1α-associated tumor biology and anti-angiogenic activity. It addresses the need for agents that suppress HIF-1α-linked tumor progression pathways.

Source 1DOIPubMed

What it does not solve

The abstract does not establish direct biochemical binding or define selectivity against alternative targets. It also does not show that computationally predicted binding sites are experimentally confirmed.

Source 1DOIPubMed

Alternatives

The abstract does not name direct alternative compounds, but it frames 2-ANPC against the broader goal of developing potent chemotherapeutic agents with anti-angiogenic activity.

Source 1DOIPubMed

Evidence Snippets

We show here that a 2-aminopyrrole derivative ... 2-ANPC ... effectively downregulates HIF-1α expression ... and HIF-1α is a novel molecular target for the 2-aminopyrrole derivative (2-ANPC).
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1apoptosis associationsupports2025Source 1DOIPubMed

2-ANPC treatment increases cleaved caspase-3-positive apoptotic cells in 4T1 tumors.

Quoted textsource-backed
an increase in apoptotic (i.e., cleaved caspase-3-positive) cells was detected in 4T1 tumors treated with 2-aminopyrrole derivative.
Claim 2computational modelingsupports2025Source 1DOIPubMed

Computational analysis identified four potential binding sites for 2-ANPC to interact with HIF-1α, HIF-1β, and the p300 complex.

Quoted textsource-backed
using various computational tools, we identified four potential binding sites for 2-ANPC to interact with HIF-1α, HIF-1β, and the p300 complex.
Claim 3in vivo activitysupports2025Source 1DOIPubMed

2-ANPC downregulates HIF-1α in vivo in the 4T1 breast cancer syngeneic model.

Quoted textsource-backed
2-ANPC's potency in downregulating HIF-1α was also shown in vivo by using the 4T1 breast cancer syngraft model.
Claim 4mechanism of actionsupports2025Source 1DOIPubMed

2-ANPC-mediated HIF-1α downregulation is due to enhanced proteasome-mediated degradation and is reversed by MG-132.

Quoted textsource-backed
The downregulation of HIF-1α expression in 2-ANPC-treated cancer cells was due to enhanced proteasome-mediated degradation, whereas the proteasome inhibitor MG-132 effectively reversed this downregulation.
Claim 5novel target claimsupports2025Source 1DOIPubMed

HIF-1α is presented as a novel molecular target for 2-ANPC.

Quoted textsource-backed
we show here, for the first time, that HIF-1α is a novel molecular target for the 2-aminopyrrole derivative (2-ANPC)
Claim 6target modulationsupports2025Source 1DOIPubMed

2-ANPC downregulates HIF-1α expression in breast, lung, and prostate cancer cell lines.

Quoted textsource-backed
2-ANPC ... effectively downregulates HIF-1α expression in a broad spectrum of cancer cell lines, including breast, lung, and prostate cancer.
Claim 7tumor responsesupports2025Source 1DOIPubMed

In 4T1 tumors, 2-ANPC downregulates VEGFR1 and VEGFR3 expression and this correlates with decreased tumor weight and size.

Quoted textsource-backed
this 2-aminopyrrole derivative also downregulated the expression of vascular endothelial growth factor receptors 1 and 3 (VEGFR1 and 3) in 4T1 tumors, which correlated with decreased tumor weight and size.